CDH17

ADC is Back: Why CDH17 This Time?

by

Recently, the biopharmaceutical sector seems to be reviving. Perhaps the BD departments of MNCs have returned from their summer breaks, reigniting the cross-ocean BD wave. On October 17, Hansoh Pharmaceutical announced a licensing collaboration with global oncology giant Roche for its CDH17 ADC new drug HS-20110. Roche will pay 80 million USD as an upfront … Read more

Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials

by
Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Lepu Biopharma’s Class 1 new drug MRG007 has been approved for clinical trials,aiming to develop treatments for locally advanced or metastatic solid tumors. Public information indicates that this is aCDH17-targeted antibody-drug conjugate (ADC),formed by conjugating a novel humanized … Read more